MX2015014424A - Construcciones de proteinas mitocondriales y sus usos. - Google Patents

Construcciones de proteinas mitocondriales y sus usos.

Info

Publication number
MX2015014424A
MX2015014424A MX2015014424A MX2015014424A MX2015014424A MX 2015014424 A MX2015014424 A MX 2015014424A MX 2015014424 A MX2015014424 A MX 2015014424A MX 2015014424 A MX2015014424 A MX 2015014424A MX 2015014424 A MX2015014424 A MX 2015014424A
Authority
MX
Mexico
Prior art keywords
disclosed
mitochondrial proteins
proteins constructs
constructs
mitochondrial
Prior art date
Application number
MX2015014424A
Other languages
English (en)
Inventor
Haya Lorberboum-Galski
Hagar Greif
Original Assignee
Bio Blast Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Blast Pharma Ltd filed Critical Bio Blast Pharma Ltd
Publication of MX2015014424A publication Critical patent/MX2015014424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0091—Oxidoreductases (1.) oxidizing metal ions (1.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

Se divulgan construcciones de proteína de fusión que comprenden una proteína mitocondrial funcional, que pueden ingresar a la mitocondria dentro de las células intactas. Además se divulgan métodos de tratamiento de los trastornos mitocondriales por las proteínas de fusión divulgadas y las composiciones correspondientes.
MX2015014424A 2013-04-15 2014-04-10 Construcciones de proteinas mitocondriales y sus usos. MX2015014424A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361811934P 2013-04-15 2013-04-15
US201361869981P 2013-08-26 2013-08-26
US14/034,224 US8912147B2 (en) 2013-04-15 2013-09-23 Mitochondrial proteins constructs and uses thereof
PCT/IL2014/050354 WO2014170896A2 (en) 2013-04-15 2014-04-10 Mitochondrial proteins constructs and uses thereof

Publications (1)

Publication Number Publication Date
MX2015014424A true MX2015014424A (es) 2016-05-18

Family

ID=51686951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014424A MX2015014424A (es) 2013-04-15 2014-04-10 Construcciones de proteinas mitocondriales y sus usos.

Country Status (13)

Country Link
US (1) US8912147B2 (es)
EP (1) EP2986629B1 (es)
JP (1) JP2016520557A (es)
KR (1) KR20150143778A (es)
AU (1) AU2014255313A1 (es)
BR (1) BR112015026017A2 (es)
CA (1) CA2909276A1 (es)
EA (1) EA201501028A1 (es)
MD (1) MD20150109A2 (es)
MX (1) MX2015014424A (es)
PE (1) PE20151774A1 (es)
SG (1) SG11201508313TA (es)
WO (1) WO2014170896A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127724A1 (en) 2016-04-12 2019-05-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins
CA3122080A1 (en) * 2018-12-06 2020-06-11 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
EP3891175A4 (en) * 2018-12-06 2022-11-09 Arcturus Therapeutics, Inc. MODIFIED PROTEINS AND RELATED TREATMENT METHODS
CN110003345A (zh) * 2019-04-03 2019-07-12 天津师范大学 一种抗迟缓爱德华氏菌的TAT-EseD重组蛋白及用途
US20220378869A1 (en) 2019-07-18 2022-12-01 Larimar Therapeutics, Inc. Use of frataxin for treating leigh syndrome, french canadian type
BR112022001657A2 (pt) * 2019-07-29 2022-03-22 Univ Indiana Trustees Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich
WO2021108659A1 (en) 2019-11-25 2021-06-03 Larimar Therapeutics, Inc. Methods for quantifying frataxin activity
CA3173130A1 (en) 2020-03-26 2021-09-30 Larimar Therapeutics, Inc. Molecules for organelle-specific protein delivery
WO2021222865A1 (en) 2020-04-30 2021-11-04 Larimar Therapeutics, Inc. Methods for treating myelin associated diseases and mitochondria associated diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283444B2 (en) * 2003-10-24 2012-10-09 Wake Forest University Non-viral delivery of compounds to mitochondria
WO2009098682A2 (en) 2008-02-04 2009-08-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for treatment of mitochondrial disorders

Also Published As

Publication number Publication date
CA2909276A1 (en) 2014-10-23
SG11201508313TA (en) 2015-11-27
PE20151774A1 (es) 2015-12-20
EA201501028A1 (ru) 2016-04-29
EP2986629A2 (en) 2016-02-24
US20140308262A1 (en) 2014-10-16
KR20150143778A (ko) 2015-12-23
WO2014170896A3 (en) 2014-12-31
AU2014255313A1 (en) 2015-09-10
BR112015026017A2 (pt) 2017-10-17
WO2014170896A2 (en) 2014-10-23
EP2986629B1 (en) 2017-11-08
JP2016520557A (ja) 2016-07-14
MD20150109A2 (ro) 2016-03-31
US8912147B2 (en) 2014-12-16

Similar Documents

Publication Publication Date Title
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
MX2019003489A (es) Moleculas del receptor de envolvimiento quimerico.
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MY193806A (en) Affinity-oligonucleotide conjugates and uses thereof
MX2017011281A (es) Conjugados de amatoxina y anticuerpos.
IL249828A0 (en) Limbal stem cells of cultured mammals, methods of their creation and uses thereof
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX2017006127A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
BR112016022841A2 (pt) cadeia j modificada
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2019003214A (es) Formulaciones de proteina de inmunoglobulina del dominio variable dual estable.
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
UY34885A (es) Proteínas de unión anti-mesotelina
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX363690B (es) Expansión de celulas madre adultas in vitro.
CL2018001565A1 (es) Inmunoglobulinas conjugadas con lisina c-terminal
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
EA201591709A1 (ru) 5-бром-индирубины
EA201791716A1 (ru) Фармацевтический состав
EA201891482A1 (ru) Модифицированные антитела для сайт-специфической конъюгации
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.
WO2014164301A3 (en) Protein formulations
EA201691049A1 (ru) Энтомотоксичные полипептиды